
    
      Women will be randomly divided into two groups; one will start Enoxaparin therapy once
      positive pregnancy test is established and the other will start Enoxaparin therapy after
      sonographic confirmation of fetal cardiac pulsation. In all women, Enoxaparin will be given
      in a dose of 40 mg/day subcutaneously and the therapy will continue until termination of
      pregnancy
    
  